212 related articles for article (PubMed ID: 28486867)
1. Hospital Length of Stay Among Patients Receiving Intermittent Versus Prolonged Piperacillin/Tazobactam Infusion in the Intensive Care Units.
Chan JD; Dellit TH; Lynch JB
J Intensive Care Med; 2018 Feb; 33(2):134-141. PubMed ID: 28486867
[TBL] [Abstract][Full Text] [Related]
2. Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.
Yusuf E; Spapen H; Piérard D
J Crit Care; 2014 Dec; 29(6):1089-95. PubMed ID: 25179412
[TBL] [Abstract][Full Text] [Related]
3. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
Yost RJ; Cappelletty DM;
Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes of Extended Versus Intermittent Infusion of Piperacillin/Tazobactam in Critically Ill Patients: A Prospective Clinical Trial.
Fan SY; Shum HP; Cheng WY; Chan YH; Leung SM; Yan WW
Pharmacotherapy; 2017 Jan; 37(1):109-119. PubMed ID: 27888542
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial Monotherapy versus Combination Therapy for the Treatment of Complicated Intra-Abdominal Infections.
Petite SE; Bauer SR; Bollinger JE; Ahrens CL; Harinstein LM
Pharmacotherapy; 2016 Nov; 36(11):1138-1144. PubMed ID: 27726155
[TBL] [Abstract][Full Text] [Related]
6. Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.
Arnold HM; Hollands JM; Skrupky LP; Smith JR; Juang PH; Hampton NB; McCormick S; Reichley RM; Hoban A; Hoffmann J; Micek ST; Kollef MH
Ann Pharmacother; 2013 Feb; 47(2):170-80. PubMed ID: 23341160
[TBL] [Abstract][Full Text] [Related]
7. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort.
Abdul-Aziz MH; Lipman J; Akova M; Bassetti M; De Waele JJ; Dimopoulos G; Dulhunty J; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Roberts JA;
J Antimicrob Chemother; 2016 Jan; 71(1):196-207. PubMed ID: 26433783
[TBL] [Abstract][Full Text] [Related]
8. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
Lodise TP; Lomaestro B; Drusano GL
Clin Infect Dis; 2007 Feb; 44(3):357-63. PubMed ID: 17205441
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of an extended-infusion piperacillin-tazobactam protocol implementation in a community teaching hospital adult intensive care unit.
Schmees PM; Bergman SJ; Strader BD; Metzke ME; Pointer S; Valenti KM
Am J Health Syst Pharm; 2016 Jun; 73(11 Suppl 3):S100-5. PubMed ID: 27208142
[TBL] [Abstract][Full Text] [Related]
10. Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: a retrospective study.
Meybeck A; Ricard JD; Barnaud G; Eveillard M; Chevrel G; Mounier R; Dreyfuss D
BMC Infect Dis; 2008 May; 8():67. PubMed ID: 18485230
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.
Winstead EM; Ratliff PD; Hickson RP; Mueller JE; Judd WR
Int J Clin Pharm; 2016 Oct; 38(5):1087-93. PubMed ID: 27333796
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Economic Impact of Empirical Extended-Infusion Piperacillin-Tazobactam in a Community Medical Center.
Brunetti L; Poustchi S; Cunningham D; Toscani M; Nguyen J; Lim J; Ding Y; Nahass RG
Ann Pharmacother; 2015 Jul; 49(7):754-60. PubMed ID: 25855703
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Rates of Nephrotoxicity Associated with Vancomycin in Combination with Piperacillin-Tazobactam Administered as an Extended versus Standard Infusion.
Mousavi M; Zapolskaya T; Scipione MR; Louie E; Papadopoulos J; Dubrovskaya Y
Pharmacotherapy; 2017 Mar; 37(3):379-385. PubMed ID: 28079263
[TBL] [Abstract][Full Text] [Related]
14. Prolonged Infusion Piperacillin-Tazobactam Decreases Mortality and Improves Outcomes in Severely Ill Patients: Results of a Systematic Review and Meta-Analysis.
Rhodes NJ; Liu J; O'Donnell JN; Dulhunty JM; Abdul-Aziz MH; Berko PY; Nadler B; Lipman J; Roberts JA
Crit Care Med; 2018 Feb; 46(2):236-243. PubMed ID: 29116995
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
Cies JJ; Shankar V; Schlichting C; Kuti JL
Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.
Schaper NC; Dryden M; Kujath P; Nathwani D; Arvis P; Reimnitz P; Alder J; Gyssens IC
Infection; 2013 Feb; 41(1):175-86. PubMed ID: 23180507
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
[TBL] [Abstract][Full Text] [Related]
18. Comparison of acute renal injury associated with intermittent and extended infusion piperacillin/tazobactam.
McCormick H; Tomaka N; Baggett S; Heierman T; LaFosse J; Gilbert S; Imhof K
Am J Health Syst Pharm; 2015 Jun; 72(11 Suppl 1):S25-30. PubMed ID: 25991590
[TBL] [Abstract][Full Text] [Related]
19. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients.
Lee GC; Liou H; Yee R; Quan CF; Neldner K
Clin Ther; 2012 Dec; 34(12):2297-300. PubMed ID: 23195962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]